Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
[Recommendations by the Swedish lung cancer group. Shorter waiting time is a quality requirement in the management of lung cancer].

Lakartidningen

Hillerdal G.
PMID: 10575882
Lakartidningen. 1999 Oct 27;96(43):4691.

No abstract available.

Cite
Hillerdal G. Rekommendationer utarbetade av Svenska lungcancerstudiegruppen. Kortare väntetider ett kvalitetskrav vid utredningar av lungcancer. [Recommendations by the Swedish lung cancer group. Shorter waiting time is a quality requirement in the management of lung cancer]. Lakartidningen. 1999;96(43):4691
Hillerdal, G. (1999). Rekommendationer utarbetade av Svenska lungcancerstudiegruppen. Kortare väntetider ett kvalitetskrav vid utredningar av lungcancer. [Recommendations by the Swedish lung cancer group. Shorter waiting time is a quality requirement in the management of lung cancer]. Lakartidningen, 96(43), 4691.
Hillerdal, G. "Rekommendationer utarbetade av Svenska lungcancerstudiegruppen. Kortare väntetider ett kvalitetskrav vid utredningar av lungcancer." [Recommendations by the Swedish lung cancer group. Shorter waiting time is a quality requirement in the management of lung cancer]. Lakartidningen vol. 96,43 (1999): 4691.
Hillerdal G. Rekommendationer utarbetade av Svenska lungcancerstudiegruppen. Kortare väntetider ett kvalitetskrav vid utredningar av lungcancer. [Recommendations by the Swedish lung cancer group. Shorter waiting time is a quality requirement in the management of lung cancer]. Lakartidningen. 1999 Oct 27;96(43):4691. Swedish. PMID: 10575882.
Copy Download .nbib Format: NLM
THE ALTERED PROGNOSIS IN TUBERCULOSIS.

Acta tuberculosea et pneumologica Scandinavica. Supplementum

HILLERDAL O.
PMID: 14160967
Acta Tuberc Pneumol Scand Suppl. 1964;56:SUPPL 56:96-8.

No abstract available.

Cite
HILLERDAL O. THE ALTERED PROGNOSIS IN TUBERCULOSIS. Acta Tuberc Pneumol Scand Suppl. 1964;56:SUPPL 56:96-8
HILLERDAL, O. (1964). THE ALTERED PROGNOSIS IN TUBERCULOSIS. Acta tuberculosea et pneumologica Scandinavica. Supplementum, 56SUPPL 56:96-8.
HILLERDAL, O. "THE ALTERED PROGNOSIS IN TUBERCULOSIS." Acta tuberculosea et pneumologica Scandinavica. Supplementum vol. 56 (1964): SUPPL 56:96-8.
HILLERDAL O. THE ALTERED PROGNOSIS IN TUBERCULOSIS. Acta Tuberc Pneumol Scand Suppl. 1964;56:SUPPL 56:96-8. PMID: 14160967.
Copy Download .nbib Format: NLM
Mesothelioma in immigrants from Turkey: Genes have a minor role.

Respiratory medicine

Metintas S, Metintas M, Ak G, Hillerdal G, Koyi H.
PMID: 34218167
Respir Med. 2021 Sep;186:106527. doi: 10.1016/j.rmed.2021.106527. Epub 2021 Jun 29.

OBJECTIVE: To examine the incidence and epidemiology of malignant mesothelioma in immigrants from Karain where there is an extraordinarily high incidence of mesothelioma, Cappadocia, Turkey, to Stockholm, Sweden, and their children over 20 years of age born in Stockholm,...

Cite
Metintas S, Metintas M, Ak G, et al. Mesothelioma in immigrants from Turkey: Genes have a minor role. Respir Med. 2021;186:106527doi: 10.1016/j.rmed.2021.106527.
Metintas, S., Metintas, M., Ak, G., Hillerdal, G., & Koyi, H. (2021). Mesothelioma in immigrants from Turkey: Genes have a minor role. Respiratory medicine, 186106527. https://doi.org/10.1016/j.rmed.2021.106527
Metintas, Selma, et al. "Mesothelioma in immigrants from Turkey: Genes have a minor role." Respiratory medicine vol. 186 (2021): 106527. doi: https://doi.org/10.1016/j.rmed.2021.106527
Metintas S, Metintas M, Ak G, Hillerdal G, Koyi H. Mesothelioma in immigrants from Turkey: Genes have a minor role. Respir Med. 2021 Sep;186:106527. doi: 10.1016/j.rmed.2021.106527. Epub 2021 Jun 29. PMID: 34218167.
Copy Download .nbib Format: NLM
Mesothelioma in immigrants from Turkey: Genes have a minor role.

Respiratory medicine

Metintas S, Metintas M, Ak G, Hillerdal G, Koyi H.
PMID: 34218167
Respir Med. 2021 Sep;186:106527. doi: 10.1016/j.rmed.2021.106527. Epub 2021 Jun 29.

OBJECTIVE: To examine the incidence and epidemiology of malignant mesothelioma in immigrants from Karain where there is an extraordinarily high incidence of mesothelioma, Cappadocia, Turkey, to Stockholm, Sweden, and their children over 20 years of age born in Stockholm,...

Cite
Metintas S, Metintas M, Ak G, et al. Mesothelioma in immigrants from Turkey: Genes have a minor role. Respir Med. 2021;186:106527doi: 10.1016/j.rmed.2021.106527.
Metintas, S., Metintas, M., Ak, G., Hillerdal, G., & Koyi, H. (2021). Mesothelioma in immigrants from Turkey: Genes have a minor role. Respiratory medicine, 186106527. https://doi.org/10.1016/j.rmed.2021.106527
Metintas, Selma, et al. "Mesothelioma in immigrants from Turkey: Genes have a minor role." Respiratory medicine vol. 186 (2021): 106527. doi: https://doi.org/10.1016/j.rmed.2021.106527
Metintas S, Metintas M, Ak G, Hillerdal G, Koyi H. Mesothelioma in immigrants from Turkey: Genes have a minor role. Respir Med. 2021 Sep;186:106527. doi: 10.1016/j.rmed.2021.106527. Epub 2021 Jun 29. PMID: 34218167.
Copy Download .nbib Format: NLM
The mortality from tuberculosis in a Swedish county.

Acta tuberculosea et pneumologica Scandinavica

HILLERDAL O.
PMID: 13954582
Acta Tuberc Pneumol Scand. 1963;42:251-62.

No abstract available.

Cite
HILLERDAL O. The mortality from tuberculosis in a Swedish county. Acta Tuberc Pneumol Scand. 1963;42:251-62
HILLERDAL, O. (1963). The mortality from tuberculosis in a Swedish county. Acta tuberculosea et pneumologica Scandinavica, 42251-62.
HILLERDAL, O. "The mortality from tuberculosis in a Swedish county." Acta tuberculosea et pneumologica Scandinavica vol. 42 (1963): 251-62.
HILLERDAL O. The mortality from tuberculosis in a Swedish county. Acta Tuberc Pneumol Scand. 1963;42:251-62. PMID: 13954582.
Copy Download .nbib Format: NLM
[Prognosis in cavitary lung tuberculosis].

Nordisk medicin

HILLERDAL O.
PMID: 13954584
Nord Med. 1963 Jul 25;70:844-7.

No abstract available.

Cite
HILLERDAL O. [Prognosis in cavitary lung tuberculosis]. Nord Med. 1963;70:844-7
HILLERDAL, O. (1963). [Prognosis in cavitary lung tuberculosis]. Nordisk medicin, 70844-7.
HILLERDAL, O. "[Prognosis in cavitary lung tuberculosis]." Nordisk medicin vol. 70 (1963): 844-7.
HILLERDAL O. [Prognosis in cavitary lung tuberculosis]. Nord Med. 1963 Jul 25;70:844-7. Swedish. PMID: 13954584.
Copy Download .nbib Format: NLM
[No title available]

Oncotarget

Hillerdal CO, Ötvös R, Szatmári T, Own SA, Hillerdal G, Dackland ÅL, Dobra K, Hjerpe A.
PMID: 29137310
Oncotarget. 2017 Sep 15;8(47):82885-82896. doi: 10.18632/oncotarget.20889. eCollection 2017 Oct 10.

The effect of chemotherapy may be improved by combining the most effective drugs based on testing the sensitivity of the individual tumor

Cite
Hillerdal CO, Ötvös R, Szatmári T, et al. . Oncotarget. 2017;8(47):82885-82896doi: 10.18632/oncotarget.20889.
Hillerdal, C. O., Ötvös, R., Szatmári, T., Own, S. A., Hillerdal, G., Dackland, �. �. L., Dobra, K., & Hjerpe, A. (2017). . Oncotarget, 8(47), 82885-82896. https://doi.org/10.18632/oncotarget.20889
Hillerdal, Carl-Olof, et al. "." Oncotarget vol. 8,47 (2017): 82885-82896. doi: https://doi.org/10.18632/oncotarget.20889
Hillerdal CO, Ötvös R, Szatmári T, Own SA, Hillerdal G, Dackland ÅL, Dobra K, Hjerpe A. . Oncotarget. 2017 Sep 15;8(47):82885-82896. doi: 10.18632/oncotarget.20889. eCollection 2017 Oct 10. PMID: 29137310; PMCID: PMC5669936.
Copy Download .nbib Format: NLM
Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma.

Genes & cancer

Ötvös R, Szulkin A, Hillerdal CO, Celep A, Yousef-Fadhel E, Skribek H, Hjerpe A, Székely L, Dobra K.
PMID: 26000095
Genes Cancer. 2015 Mar;6(3):119-128. doi: 10.18632/genesandcancer.56.

We propose to assess the therapeutic value of biomarker-guided individualized chemotherapy in patients with metastasizing lung adenocarcinoma. In this study, we used primary cells from pleural effusions from sixteen patients diagnosed with adenocarcinomas originating in the lung and from...

Cite
Ötvös R, Szulkin A, Hillerdal CO, et al. Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma. Genes Cancer. 2015;6(3):119-128doi: 10.18632/genesandcancer.56.
Ötvös, R., Szulkin, A., Hillerdal, C. O., Celep, A., Yousef-Fadhel, E., Skribek, H., Hjerpe, A., Székely, L., & Dobra, K. (2015). Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma. Genes & cancer, 6(3), 119-128. https://doi.org/10.18632/genesandcancer.56
Ötvös, Rita, et al. "Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma." Genes & cancer vol. 6,3 (2015): 119-128. doi: https://doi.org/10.18632/genesandcancer.56
Ötvös R, Szulkin A, Hillerdal CO, Celep A, Yousef-Fadhel E, Skribek H, Hjerpe A, Székely L, Dobra K. Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma. Genes Cancer. 2015 Mar;6(3):119-128. doi: 10.18632/genesandcancer.56. PMID: 26000095; PMCID: PMC4426949.
Copy Download .nbib Format: NLM
Intrabronchial stents in heterogenous emphysema: a highly selected material followed 5 years.

Journal of thoracic disease

Hillerdal G, Koyi H.
PMID: 32802431
J Thorac Dis. 2020 Jul;12(7):3524-3528. doi: 10.21037/jtd-19-4082.

BACKGROUND: Endobronchial lung volume reduction (EBVR) with one-way valves introduced into the most diseased lobe of the lung is a non-invasive method to improve lung function in patients with severe heterogenous emphysema. The problem is to select the right...

Cite
Hillerdal G, Koyi H. Intrabronchial stents in heterogenous emphysema: a highly selected material followed 5 years. J Thorac Dis. 2020;12(7):3524-3528doi: 10.21037/jtd-19-4082.
Hillerdal, G., & Koyi, H. (2020). Intrabronchial stents in heterogenous emphysema: a highly selected material followed 5 years. Journal of thoracic disease, 12(7), 3524-3528. https://doi.org/10.21037/jtd-19-4082
Hillerdal, Gunnar, and Koyi, Hirsh. "Intrabronchial stents in heterogenous emphysema: a highly selected material followed 5 years." Journal of thoracic disease vol. 12,7 (2020): 3524-3528. doi: https://doi.org/10.21037/jtd-19-4082
Hillerdal G, Koyi H. Intrabronchial stents in heterogenous emphysema: a highly selected material followed 5 years. J Thorac Dis. 2020 Jul;12(7):3524-3528. doi: 10.21037/jtd-19-4082. PMID: 32802431; PMCID: PMC7399418.
Copy Download .nbib Format: NLM
Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden.

Lung cancer international

Koyi H, Hillerdal G, Andersson O, Kölbeck KG, Liv P, Brandén E.
PMID: 26316949
Lung Cancer Int. 2015;2015:317868. doi: 10.1155/2015/317868. Epub 2015 Jul 14.

An increasing proportion of cancer patients are aged >65 years and many are aged >70 years. Treatment of the elderly with lung cancer has, therefore, become an important issue; so we performed a retrospective study of our patients to...

Cite
Koyi H, Hillerdal G, Andersson O, et al. Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden. Lung Cancer Int. 2015;2015:317868doi: 10.1155/2015/317868.
Koyi, H., Hillerdal, G., Andersson, O., Kölbeck, K. G., Liv, P., & Brandén, E. (2015). Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden. Lung cancer international, 2015317868. https://doi.org/10.1155/2015/317868
Koyi, Hirsh, et al. "Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden." Lung cancer international vol. 2015 (2015): 317868. doi: https://doi.org/10.1155/2015/317868
Koyi H, Hillerdal G, Andersson O, Kölbeck KG, Liv P, Brandén E. Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden. Lung Cancer Int. 2015;2015:317868. doi: 10.1155/2015/317868. Epub 2015 Jul 14. PMID: 26316949; PMCID: PMC4517544.
Copy Download .nbib Format: NLM
Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors.

Molecular therapy. Methods & clinical development

Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M.
PMID: 26015949
Mol Ther Methods Clin Dev. 2014 Mar 05;1:14001. doi: 10.1038/mtm.2014.1. eCollection 2014.

Adoptive T-cell therapy of cancer is a treatment strategy where T cells are isolated, activated, in some cases engineered, and expanded ex vivo before being reinfused to the patient. The most commonly used T-cell expansion methods are either anti-CD3/CD28...

Cite
Jin C, Yu D, Hillerdal V, et al. Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Mol Ther Methods Clin Dev. 2014;1:14001doi: 10.1038/mtm.2014.1.
Jin, C., Yu, D., Hillerdal, V., Wallgren, A., Karlsson-Parra, A., & Essand, M. (2014). Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Molecular therapy. Methods & clinical development, 114001. https://doi.org/10.1038/mtm.2014.1
Jin, Chuan, et al. "Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors." Molecular therapy. Methods & clinical development vol. 1 (2014): 14001. doi: https://doi.org/10.1038/mtm.2014.1
Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M. Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Mol Ther Methods Clin Dev. 2014 Mar 05;1:14001. doi: 10.1038/mtm.2014.1. eCollection 2014. PMID: 26015949; PMCID: PMC4362340.
Copy Download .nbib Format: NLM
Precision patients: Selection practices and moral pathfinding in experimental oncology.

Sociology of health & illness

Dam MS, Green S, Bogicevic I, Hillersdal L, Spanggaard I, Rohrberg KS, Svendsen MN.
PMID: 34993996
Sociol Health Illn. 2022 Jan 07; doi: 10.1111/1467-9566.13424. Epub 2022 Jan 07.

This paper addresses selection practices in a Danish phase 1 unit specialised in precision medicine in the field of oncology. Where precision medicine holds the ambition of selecting genetically fit medicine for the patient, we find that precision medicine...

Cite
Dam MS, Green S, Bogicevic I, et al. Precision patients: Selection practices and moral pathfinding in experimental oncology. Sociol Health Illn. 2022;doi: 10.1111/1467-9566.13424.
Dam, M. S., Green, S., Bogicevic, I., Hillersdal, L., Spanggaard, I., Rohrberg, K. S., & Svendsen, M. N. (2022). Precision patients: Selection practices and moral pathfinding in experimental oncology. Sociology of health & illness, . https://doi.org/10.1111/1467-9566.13424
Dam, Mie S, et al. "Precision patients: Selection practices and moral pathfinding in experimental oncology." Sociology of health & illness vol. (2022). doi: https://doi.org/10.1111/1467-9566.13424
Dam MS, Green S, Bogicevic I, Hillersdal L, Spanggaard I, Rohrberg KS, Svendsen MN. Precision patients: Selection practices and moral pathfinding in experimental oncology. Sociol Health Illn. 2022 Jan 07; doi: 10.1111/1467-9566.13424. Epub 2022 Jan 07. PMID: 34993996.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries